CORRIGENDUM

Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum]

Kameoka Y, Kishi F, Koura M, et al. *Drug Des Devel Ther.* 2019;13:555–568.

The authors have advised that there was an error in the text.

Page 561, beginning at the left-hand bottom of the page, “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 4.42 (1.36–7.57)×10⁹ cells/L vs 3.14

(1.48–15.7)×10⁹ cells/L (Figure S3A). The number of granulocytes decreased: 0.15 (0.05–1.04)×10⁹ cells/L vs 0.22 (0.04–0.69)×10⁹ cells/L (Figure S3B).” should instead read “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 2.11 (1.36–2.44)×10⁹ cells/L vs 3.14 (1.48–15.7)×10⁹ cells/L (Figure S3A). The number of granulocytes decreased: 0.055 (0.03–0.08)×10⁹ cells/L vs 0.22 (0.04–0.69)×10⁹ cells/L (Figure S3B).”

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>